Trial Profile
Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs DTaP poliovirus vaccine (Primary) ; DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-meningococcal vaccine group C conjugate (Primary) ; Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Meningococcal vaccine group C conjugate
- Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 08 Nov 2013 New source identified and integrated (ClinicalTrials.gov; NCT00891176).
- 27 Feb 2013 New trial record